The American Society for Radiation Oncology (ASTRO) is an Accreditation Council for Continuing Medical Education (ACCME)-accredited CME provider and complies with the ACCME Standards for Commercial Support. In accordance with these Standards, the ASTRO Conflict of Interest Policy and the Council for Medical Specialty Societies’ Code for Interactions with Companies, ASTRO is disclosing here the relationships between faculty of the 2021 Multidisciplinary Thoracic Cancers Symposium and other entities related to oncology or radiation therapy.

Explanatory notes:
- ASTRO uses the information disclosed to identify and manage any potential conflicts of interest that may arise in carrying out the responsibilities of the committees.
- Committee members disclose their own relationships and those of their immediate family members.
- There is no “minimum value” threshold for disclosure.
- Disclosure time period covers relationships held or payments received during the year leading up to the disclosure.
- The disclosure information is relevant only to the planning of the 2021 Multidisciplinary Thoracic Cancers Symposium and should be considered out of date after this time.
- This information may be different from disclosure information provided in other contexts by the committee members because of variation in disclosure requests for these other purposes.

Employment = positions held at the time of disclosure. These include both full- and part-time relationships, whether compensated or uncompensated.

Compensation/Remuneration/Funding = includes consultant/advisory roles, honoraria, research funding, travel expenses, in-kind donation, etc. If a committee member receives an honorarium and donates it to charity, the honorarium is disclosed. If a committee member declines an honorarium and it is paid directly to charity, the honorarium is not included. Honoraria from accredited CME providers are not included.

Ownership or Investment Interests = includes stock, stock options, partnership, royalties or patents. Stocks in mutual funds, blind trusts or other holdings that are not controlled by the individual or an immediate family member are not included.

Leadership Positions = positions held in other organizations or entities.


### 2021 Multidisciplinary Thoracic Cancers Symposium Steering Committee - Potential Conflict of Interest (COI) Disclosures

<table>
<thead>
<tr>
<th>Member</th>
<th>Employment</th>
<th>Compensation / Remuneration / Funding</th>
<th>Leadership Positions</th>
<th>Ownership or Investment Interests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biniam Kidane, MD, MSc, FRCSC</td>
<td>University of Manitoba Health Sciences Centre: Thoracic Surgeon</td>
<td>AstraZeneca: Consultant</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Member</td>
<td>Employment</td>
<td>Compensation / Remuneration / Funding</td>
<td>Leadership Positions</td>
<td>Ownership or Investment Interests</td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>----------------------------------</td>
</tr>
</tbody>
</table>
| David Carbone, MD, PhD | The Ohio State University Comprehensive Cancer Center: Professor            | AstraZeneca: Honoraria, Travel Expenses, Advisory Board  
Boehringer-Ingelheim: Consultant  
Bristol Myers-Squibb: Research Grants, Travel Expenses, Advisory Board  
EMD Serono: Travel Expenses, Advisory Board  
Genentech/Roche: Travel Expenses, Advisory Board  
Janssen: Travel Expenses, Advisory Board  
Merck: Travel Expenses, Advisory Board  
Novartis: Consultant, Travel Expenses  
Daiichi Sankyo: Advisory Board  
Glaxo Smith Kline: Consultant, Travel Expenses  
Bristol Myers Squibb Japan: Consultant  
Elsa: Advisory Board  
Flame Biosciences: Advisory Board  
Gritstone Oncology: Advisory Board  
Intellisphere (GI Therapeutics): Consultant  
Mirati Therapeutics: Consultant  
Johnson & Johnson: Consultant  
Novocure: Consultant  
OncoCyte: Consultant  
Roche China: Consultant  
Sanofi: Advisory Board  
Seattle Genetics: Consultant, Advisory Board  
Amgen: Consultant | The Ohio State University Comprehensive Cancer Center: Director Thoracic Oncology Center | None                                                                                           |
| Gregory P. Kalemkerian, MD | University of Michigan                                                      | Merck: Research Grants  
Takeda: Research Grants  
Abbvie: Research Grants  
Ascentage: Research Grants  
Blueprint, Daiichi-Sankyo: Research Grants | None                                                                                           | None                             |
| Jeffrey Bradley, MD, FASTRO | Emory University School of Medicine: Professor  
Washington University School of Medicine: Professor (relationship ended 7/31/19) | Genentech, Inc: Honoraria, Advisory Board  
Varian Medical Systems, Inc: Consultant  
Mevion Medical Systems: Honoraria, Advisory Board | American College of Radiology: Lung Cancer Committee Chair  
American Radium Society Executive Committee: Member | None                             |
| Linda Martin, MD, MPH  | University of Virginia Health Systems                                       | AstraZeneca: Advisory Board  
Pacira Pharmaceuticals: Advisory Board  
On Target Laboratories: Other: Steering Committee for ELUCIDATE trial (OTL 38) | Alliance: Thoracic Surgery Committee Vice Chair  
Alliance Foundation: Principal Investigator | None                             |
<table>
<thead>
<tr>
<th>Member</th>
<th>Employment</th>
<th>Compensation / Remuneration / Funding</th>
<th>Leadership Positions</th>
<th>Ownership or Investment Interests</th>
</tr>
</thead>
</table>
| Marina Garassino, MD | University of Chicago | **MSD Oncology:** Research Grants, Honoraria, Speaker's Bureau, Advisory Board  
**AstraZeneca/Med Immune:** Research Grants, Honoraria  
**AstraZeneca:** Research Grants, Honoraria, Travel Expenses, Advisory Board  
**Glaxo Smith Kline:** Research Grants, Honoraria Advisory Board  
**Takeda:** Research Grants, Honoraria, Advisory Board  
**Bristol Myers Squibb:** Research Grants  
**Novartis:** Research Grants  
**Sanofi:** Research Grants, Advisory Board  
**Celgene:** Research Grants  
**Daiichi Sankyo:** Research Grants, Advisory Board  
**Incyte:** Research Grants, Advisory Board  
**Seattle Genetics:** Advisory Board  
**Eli Lilly:** Research Grants, Advisory Board  
**Bayer:** Research Grants, Advisory Board  
**Blueprint Medicines:** Advisory Board  
**Janssen:** Research Grants, Advisory Board  
**Medscape:** Honoraria  
**Mirati Therapeutics Inc:** Advisory Board  
**Regeneron:** Advisory Board  
**S.O.S. S.r.l.:** Honoraria  
**WebMD:** Honoraria  
**Exelixis:** Research Grants  
**Ispen Bioscience:** Research Grants  
**Medimmune:** Research Grants  
**Merck:** Research Grants  
**Otsuka Pharmaceutical Italy:** Research Grants  
**Spectrum Pharmaceuticals:** Research Grants  
**Turning Point Therapeutics:** Research Grants | None | None |
| Sue Yom, MD, PhD     | University of California | **Genentech:** Research Grants  
**ASTRO:** Honorarium  
**Up to Date:** Other: Chapter royalty  
**Merck:** Research Grants  
**Bristol-Myers Squibb:** Research Grants  
**Springer:** Other: Book royalty  
**BioMimetics:** Research Grants | ASTRO: Deputy Editor  
American Radium Society: President  
National Cancer Institute: Head and Neck Steering Committee Co-chair | None |
<table>
<thead>
<tr>
<th>Member</th>
<th>Employment</th>
<th>Compensation / Remuneration / Funding</th>
<th>Leadership Positions</th>
<th>Ownership or Investment Interests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vickie R. Shannon, MD</td>
<td>University of Texas MD Anderson Cancer Center: Professor</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

2021 Multidisciplinary Thoracic Cancers Symposium Program Committee - Potential Conflict of Interest (COI) Disclosures

<table>
<thead>
<tr>
<th>Name</th>
<th>Employment</th>
<th>Compensation / Remuneration / Funding</th>
<th>Leadership Positions</th>
<th>Ownership or Investment Interests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Long, MD, MPH</td>
<td>University of North Carolina School of Medicine: Assistant Professor</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Kristin Higgins, MD</td>
<td>Emory University</td>
<td>AstraZeneca: Consultant</td>
<td>NRG: Board of Directors</td>
<td>None</td>
</tr>
<tr>
<td>Kurt A. Schalper, MD, PhD</td>
<td>Yale University: Assistant Professor</td>
<td>Clinica Alemana Santiago: Consultant</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Shattuck Labs: Consultant, Advisory Board</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>EMD Serono: Advisory Board</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Agenus: Advisory Board</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Genoptix/Navigate (Novartis): Research Grants</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tesaro/GSK: Research Grants</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Surface Oncology: Research Grants</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Merck: Research Grants</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bristol-Myers Squibb: Research Grants</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Eli Lilly: Research Grants</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ribon Therapeutics: Research Grants</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PeerView: Speaker's Bureau</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Genmab: Speaker’s Bureau</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Genentech: Research Grants</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>AstraZeneca: Research Grants</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mark K. Ferguson, MD</td>
<td>University of Chicago: Physician</td>
<td>Elsevier: Royalties</td>
<td>International Society for Diseases of the Esophagus (ISDE): Executive Director: Liaison between ISDE and management company</td>
<td>None</td>
</tr>
<tr>
<td>Percy Lee, MD</td>
<td>University of Texas MD Anderson Cancer Center: Professor and Section Chief of Thoracic Radiation Oncology UCLA Medical Center: Professor (Relationship ended 10/1/2019)</td>
<td>Viewray: Research Grants, Honoraria, Consultant, Travel Expenses</td>
<td>AAPM: AAPM HYTEC Thoracic TCP Sub-committee Co-chair</td>
<td>None</td>
</tr>
<tr>
<td>Member</td>
<td>Employment</td>
<td>Compensation / Remuneration / Funding</td>
<td>Leadership Positions</td>
<td>Ownership or Investment Interests</td>
</tr>
<tr>
<td>--------</td>
<td>------------</td>
<td>--------------------------------------</td>
<td>----------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>Ramaswamy Govindan, MD</td>
<td>Washington University School of Medicine: Professor</td>
<td>None</td>
<td>IASLC: Chair, CMS Committee TCGA: Co-Chair, Lung Cancer Disease Working Group</td>
<td>None</td>
</tr>
</tbody>
</table>